AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
Dunne PD, McArt DG, Blayney JK, Kalimutho M, Greer S, Wang T, Srivastava S, Ong CW, Arthur K, Loughrey M, Redmond K, Longley DB, Salto-Tellez M, Johnston PG, Van Schaeybroeck S.
Dunne PD, et al.
Clin Cancer Res. 2014 Jan 1;20(1):164-75. doi: 10.1158/1078-0432.CCR-13-1354. Epub 2013 Oct 29.
Clin Cancer Res. 2014.
PMID: 24170546
Free PMC article.